TY - JOUR
T1 - Should doctors prescribe cannabinoids?
AU - Farrell, Michael
AU - Buchbinder, Rachelle
AU - Hall, Wayne
PY - 2014
Y1 - 2014
N2 - The medical use of cannabis was advocated in the United States
in the 1970s and 1980s when clinical trials of oral synthetic
tetrahydrocannabinol (THC) and other oral synthetic
cannabinoids reported efficacy in controlling nausea in patients
with cancer who were undergoing chemotherapy.1 Dronabinol
(an oral synthetic THC) was approved by the Food and Drug
Administration in 1985 for this indication,1 but it was not widely
used because patients were unable to titrate doses or disliked
its psychoactive effects.1 It is still available in the US, United
Kingdom, and the rest of Europe.
Box 1 outlines the different formulations of cannabinoids, the
term we use for the sake of clarity and convenience to refer to
synthetic cannabinoids and drugs derived from the cannabis
plant, such as nabiximols. Box 2 lists indications for which
cannabinoids have been approved for medical use.
In the US, the smoking of cannabis has been advocated for
medicinal purposes.1 Since 1996, 20 US states and the District
of Columbia have legislated (11 after citizen initiated
referendums) to allow the medical use of cannabis, often to treat
a much broader range of indications than those approved by the
FDA or other regulators (see box 2).2 In California, for example,
doctors can recommend cannabis for any medical use if they
believe that the patient may benefit.2 These laws have created
clinical conundrums for doctors in these US states.3
In the UK a cannabis based medical extract, nabiximols (see
box 1)4 has been approved for ?symptom improvement in
patients with moderate to severe spasticity due to multiple
sclerosis who have not responded adequately to other
anti-spasticity medication and who demonstrate clinically
significant improvement in spasticity related symptoms during
an initial trial of therapy.on a named patient basis.?5 Should doctors consider prescribing cannabinoids for this
indication? Should they consider prescribing nabiximols off
label for other chronic conditions? What should doctors do if
their patients disclose that they are smoking cannabis for medical
purposes?
AB - The medical use of cannabis was advocated in the United States
in the 1970s and 1980s when clinical trials of oral synthetic
tetrahydrocannabinol (THC) and other oral synthetic
cannabinoids reported efficacy in controlling nausea in patients
with cancer who were undergoing chemotherapy.1 Dronabinol
(an oral synthetic THC) was approved by the Food and Drug
Administration in 1985 for this indication,1 but it was not widely
used because patients were unable to titrate doses or disliked
its psychoactive effects.1 It is still available in the US, United
Kingdom, and the rest of Europe.
Box 1 outlines the different formulations of cannabinoids, the
term we use for the sake of clarity and convenience to refer to
synthetic cannabinoids and drugs derived from the cannabis
plant, such as nabiximols. Box 2 lists indications for which
cannabinoids have been approved for medical use.
In the US, the smoking of cannabis has been advocated for
medicinal purposes.1 Since 1996, 20 US states and the District
of Columbia have legislated (11 after citizen initiated
referendums) to allow the medical use of cannabis, often to treat
a much broader range of indications than those approved by the
FDA or other regulators (see box 2).2 In California, for example,
doctors can recommend cannabis for any medical use if they
believe that the patient may benefit.2 These laws have created
clinical conundrums for doctors in these US states.3
In the UK a cannabis based medical extract, nabiximols (see
box 1)4 has been approved for ?symptom improvement in
patients with moderate to severe spasticity due to multiple
sclerosis who have not responded adequately to other
anti-spasticity medication and who demonstrate clinically
significant improvement in spasticity related symptoms during
an initial trial of therapy.on a named patient basis.?5 Should doctors consider prescribing cannabinoids for this
indication? Should they consider prescribing nabiximols off
label for other chronic conditions? What should doctors do if
their patients disclose that they are smoking cannabis for medical
purposes?
UR - http://www.bmj.com/content/bmj/348/bmj.g2737.full.pdf
U2 - 10.1136/bmj.g2737
DO - 10.1136/bmj.g2737
M3 - Comment / Debate
SN - 2044-6055
VL - 348
SP - 1
EP - 5
JO - BMJ Open
JF - BMJ Open
M1 - g2737
ER -